Evolent Health, Inc. Q2 2026 Earnings Recap

EVH Q2 2026 August 11, 2026

Get alerts when EVH reports next quarter

Evolent’s shares surged 28.2% following an earnings report that beat expectations on revenue growth, early positive performance from new contracts, and accelerating AI-driven efficiency gains.

Earnings Per Share Beat

$0.02 vs $-0.01 est.

+292.1% surprise

Revenue Beat

652520000 vs 597694900 est.

+9.2% surprise

Market Reaction

1-Day +1.71%

See EVH alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q2 revenue rose 31% sequentially to $653 million, driven by new and expanded customer partnerships.
Adjusted EBITDA grew 27% quarter-over-quarter to $28 million, supported by higher volumes and operational improvements.
Medical Expense Ratio (MER) increased to 95% from 93% due to the May 2026 launch of the Highmark contract.
Strong contract renewal momentum, including key agreements with Aetna, Highmark, and a regional Blue Cross plan, providing visibility into 2027.
AI-powered authorization approvals reached 75%, up from 55%, streamlining claims processing and reducing administrative burdens, signaling meaningful cost and productivity improvements.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit EVH on AllInvestView.